Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook

被引：2

作者：

Zhou, Wenhao ^{[1
]}

Lu, Xiaojun ^{[1
]}

Tian, Feng ^{[2
]}

Luo, Qianming ^{[3
]}

Zhou, Weihang ^{[3
]}

Yang, Siyuan ^{[3
]}

Li, Wenxuan ^{[4
]}

Yang, Yongjun ^{[4
]}

Shi, Minfeng ^{[5
]}

Zhou, Tie ^{[1
]}

机构：

[1] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Dept Urol, Shanghai 200434, Peoples R China

[2] Shanghai Eighth Peoples Hosp, Dept Urol, Shanghai 200235, Peoples R China

[3] Tongji Univ, Sch Med, Shanghai 200092, Peoples R China

[4] Naval Med Univ, Coll Clin Med, Shanghai 200433, Peoples R China

[5] Naval Med Univ, Changhai Hosp, Reprod Ctr, Shanghai 200433, Peoples R China

来源：

VACCINES | 2024年 / 12卷 / 12期

关键词：

prostate cancer; cancer vaccines; immunotherapy; combination therapies; PERSONALIZED PEPTIDE VACCINATION; ANDROGEN DEPRIVATION THERAPY; PHASE I/II TRIAL; SIPULEUCEL-T; CELLULAR IMMUNOTHERAPY; IMMUNOLOGICAL EFFICACY; CLINICAL-TRIAL; DNA VACCINES; II TRIAL; ANTIGEN;

D O I：

10.3390/vaccines12121384

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prostate cancer is a prevalent cancer in elderly men, and immunotherapy has emerged as a promising treatment approach in recent years. The aim of immunotherapy is to stimulate the body's immune system to target and destroy cancer cells. Cancer vaccines that are highly specific, safe, and capable of creating long-lasting immune responses are a key focus in cancer immunotherapy research. Despite progress in clinical trials showing positive results, the practical use of cancer vaccines still encounters various obstacles. The complexity of the immune microenvironment and variations in the immune systems of individual patients have hindered the progress of research on prostate cancer vaccines. This review examines the history and mechanisms of cancer vaccines, summarizes recent clinical research findings, and explores future directions in the development of prostate cancer vaccines.

引用

页数：15

共 80 条

[21] Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer [J].

Kantoff, Philip W. ;

Gulley, James L. ;

Pico-Navarro, Cesar .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :124-+

[22] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[23] Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study [J].

Kuebler, Hubert ;

Scheel, Birgit ;

Gnad-Vogt, Ulrike ;

Miller, Kurt ;

Schultze-Seemann, Wolfgang ;

vom Dorp, Frank ;

Parmiani, Giorgio ;

Hampel, Christian ;

Wedel, Steffen ;

Trojan, Lutz ;

Jocham, Dieter ;

Maurer, Tobias ;

Rippin, Gerd ;

Fotin-Mleczek, Mariola ;

von der Muelbe, Florian ;

Probst, Jochen ;

Hoerr, Ingmar ;

Kallen, Karl-Josef ;

Lander, Thomas ;

Stenzl, Arnulf .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[24] Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer [J].

Kyriakopoulos, Christos E. ;

Eickhoff, Jens C. ;

Ferrari, Anna C. ;

Schweizer, Michael T. ;

Wargowski, Ellen ;

Olson, Brian M. ;

McNeel, Douglas G. .

CLINICAL CANCER RESEARCH, 2020, 26 (19) :5162-5171

[25] Exosomes: Versatile Nano Mediators of Immune Regulation [J].

Li, Qi ;

Wang, Helei ;

Peng, Hourong ;

Ting Huyan ;

Cacalano, Nicholas A. .

CANCERS, 2019, 11 (10)

[26] Cancer vaccines: the next immunotherapy frontier [J].

Lin, Matthew J. ;

Svensson-Arvelund, Judit ;

Lubitz, Gabrielle S. ;

Marabelle, Aurelien ;

Melero, Ignacio ;

Brown, Brian D. ;

Brody, Joshua D. .

NATURE CANCER, 2022, 3 (08) :911-926

[27] DNA vaccines: an historical perspective and view to the future [J].

Liu, Margaret A. .

IMMUNOLOGICAL REVIEWS, 2011, 239 :62-84

[28] Cancer DNA vaccines: current preclinical and clinical developments and future perspectives [J].

Lopes, Alessandra ;

Vandermeulen, Gaelle ;

Preat, Veronique .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)

[29]

Lorentzen CL, 2022, LANCET ONCOL, V23, pE450, DOI 10.1016/S1470-2045(22)00372-2

[30] Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity [J].

Madan, Ravi A. ;

Gulley, James L. .

TRANSLATIONAL CANCER RESEARCH, 2016, 5 :S1333-S1335

← 1 2 3 4 5 6 7 8 →